Impact of hormone replacement therapy use on mammographic screening outcomes

Cancer Causes and Control

Volumn 24, Issue 7, 2013, Pages 1417-1426

  Beckmann, Kerri R ^a   Farshid, Gelareh ^b   Roder, David M ^c   Hiller, Janet E ^d   Lynch, John W ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Clinical Services   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

Breast neoplasm; Hormone replacement therapy; Mammography; Screening

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; AUSTRALIA; BREAST BIOPSY; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DRUG USE; FEMALE; HORMONE SUBSTITUTION; HUMAN; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NEEDLE BIOPSY; PREDICTIVE VALUE; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MAMMOGRAPHY; MIDDLE AGED; NEOPLASM INVASIVENESS;

EID: 84878910502     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0221-1     Document Type: Article

References (51)

1. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289(24):3243-3253. doi: 10.1001/jama.289.24.3243 (Pubitemid 37430077)
2. Reeves GK, Beral V, Green J, Gathani T, Bull D (2006) Hormonal therapy for menopause and breast-cancer risk by histological type: A cohort study and meta-analysis. Lancet Oncol 7(11):910-918. doi: 10.1016/S1470-2045(06)70911-1 (Pubitemid 44615945)
3. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92(4):328-332 (Pubitemid 30117736)
4. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr (2008) Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 17(11):3150-3160. doi: 10.1158/1055-9965.EPI-08-0435
5. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254-3263. doi: 10.1001/jama.289.24.3254 (Pubitemid 37430078)
6. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F, Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK, Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ, Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A, Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, Norat T, Riboli E, Panico S, Masala G, Gonzalez CA, Berrino F (2011) Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 128(1):144-156. doi: 10.1002/ijc.25314
7. Boyd NF, Martin LJ, Li Q, Sun L, Chiarelli AM, Hislop G, Yaffe MJ, Minkin S (2006) Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer. Cancer Epidemiol Biomarkers Prev 15(5):961-966. doi: 10.1158/1055-9965.EPI-05-0762 (Pubitemid 43823524)
8. Hofvind S, Moller B, Thoresen S, Ursin G (2006) Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens. Int J Cancer 118(12):3112-3117. doi: 10.1002/ijc.21742
9. Roman R, Sala M, Salas D, Ascunce N, Zubizarreta R, Castells X (2012) Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening. Ann Oncol 23(1):104-111. doi: 10.1093/annonc/mdr032
10. Kavanagh AM, Mitchell H, Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355(9200):270-274. doi: 10.1016/S0140-6736(99)07319-5 (Pubitemid 30068519)
11. Banks E (2001) Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: A review. J Med Screen 8(1):29-34 (Pubitemid 32467573)
12. Kavanagh AM, Cawson J, Byrnes GB, Giles GG, Marr G, Tong B, Gertig DM, Hopper JL (2005) Hormone replacement therapy, percent mammographic density, and sensitivity of mammography. Cancer Epidemiol Biomarkers Prev 14(5):1060-1064. doi: 10.1158/1055-9965.EPI-04-0165 (Pubitemid 40656448)
13. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 329(7464):477. doi: 10.1136/bmj.329.7464.477
14. Banks E, Reeves G, Beral V, Bull D, Crossley B, Simmonds M, Hilton E, Bailey S, Barrett N, Briers P, English R, Jackson A, Kutt E, Lavelle J, Rockall L, Wallis MG, Wilson M, Patnick J (2004) Impact of use of hormone replacement therapy on false positive recall in the NHS breast screening programme: results from the Million Women Study. BMJ 328(7451):1291-1292. doi: 10.1136/bmj.328. 7451.1291 (Pubitemid 38703488)
15. Chiarelli AM, Kirsh VA, Klar NS, Shumak R, Jong R, Fishell E, Yaffe MJ, Boyd NF (2006) Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev 15(10):1856-1862. doi: 10.1158/1055-9965.EPI-06-0290 (Pubitemid 44664260)
16. Litherland JC, Stallard S, Hole D, Cordiner C (1999) The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol 54(5):285-288 (Pubitemid 29237805)
17. Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM (2010) Ductal carcinoma in situ: risk factors and impact of screening. J Natl Cancer Inst Monogr 41:113-116. doi: 10.1093/jncimonographs/lgq024
18. Calvocoressi L, Stowe MH, Carter D, Claus EB (2012) Postmenopausal hormone therapy and ductal carcinoma in situ: A population-based case-control study. Cancer Epidemiol 36(2):161-168. doi: 10.1016/j.canep.2012.01.001
19. Taylor AW, MacLennan AH, Avery JC (2006) Postmenopausal hormone therapy: who now takes it and do they differ from non-users? Aust N Z J Obstet Gynaecol 46(2):128-135. doi: 10.1111/j.1479-828X.2006.00542.x
20. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative group on hormonal factors in breast cancer. Lancet 350(9084):1047-1059 (Pubitemid 27437855)
21. Zbuk K, Anand SS (2012) Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 66(1):1-7. doi: 10.1136/jech.2008.083774
22. MacLennan AH, Gill TK, Broadbent JL, Taylor AW (2009) Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 12(2):122-130. doi: 10.1080/13697130802666251
23. Roman R, Sala M, De La Vega M, Natal C, Galceran J, Gonzalez-Roman I, Baroja A, Zubizarreta R, Ascunce N, Salas D, Castells X (2011) Effect of false-positives and women's characteristics on long-term adherence to breast cancer screening. Breast Cancer Res Treat 130(2):543-552. doi: 10.1007/s10549-011-1581-4
24. BreastScreen SA (2010) The impact of BreastScreen SA, 20 year report 1989-2008: with trend data for 1989-2004. Government of South Australia Adelaide
25. National Breast Cancer Centre (2002) Breast imaging: A guide for practice. National Breast Cancer Centre Camperdown NSW
26. Australian Bureau of Statistics (2008) Information paper: an introduction to socio-economic indexes for areas (SEIFA), 2006 ABS, Canberra
27. Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702-706 (Pubitemid 38405384)
28. StataCorp (2010) Stata statistical software: release 12. StatCorp LP, College Station
29. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360(6):573-587. doi: 10.1056/NEJMoa0807684
30. Henrich JB, Kornguth PJ, Viscoli CM, Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51(12):1277-1283 (Pubitemid 29009528)
31. Persson I, Thurfjell E, Bergstrom R, Holmberg L (1997) Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72(5):758-761. doi: 10.1002/(SICI)1097-0215(19970904)72:5<758:AID-IJC9>3. 0.CO;2-R (Pubitemid 27431516)
32. Kavanagh AM, Davidson N, Jolley D, Heuzenroeder L, Chapman A, Evans J, Gertig DM, Amos A (2006) Determinants of false positive recall in an Australian mammographic screening program. Breast 15(4):510-518. doi: 10.1016/j.breast. 2005.09.006 (Pubitemid 44109120)
33. Kavanagh AM, Giles GG, Mitchell H, Cawson JN (2000) The sensitivity, specificity, and positive predictive value of screening mammography and symptomatic status. J Med Screen 7(2):105-110
34. Sweeney KJ, Boran S, Fitzpatrick P, Merrigan AB, Moran R, Flanagan F, Kerin MJ (2009) Postmenopausal hormone therapy and prevalent round screening mammography. Int J Cancer 124(6):1490-1491. doi: 10.1002/ijc.24081
35. Dietel M (2010) Hormone replacement therapy (HRT), breast cancer and tumor pathology. Maturitas 65(3):183-189. doi: 10.1016/j.maturitas.2009.11.005
36. Seradour B, Esteve J, Heid P, Jacquemier J (1999) Hormone replacement therapy and screening mammography: analysis of the results in the Bouches du Rhone programme. J Med Screen 6(2):99-102 (Pubitemid 29320847)
37. Crouchley K, Wylie E, Khong E (2006) Hormone replacement therapy and mammographic screening outcomes in Western Australia. J Med Screen 13(2):93-97. doi: 10.1258/096914106777589588 (Pubitemid 43925924)
38. Warren R (2004) Hormones and mammographic breast density. Maturitas 49(1):67-78. doi: 10.1016/j.maturitas.2004.06.013 (Pubitemid 39209373)
39. Weedon-Fekjaer H, Tretli S, Aalen OO (2010) Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening. Stat Methods Med Res 19(5):507-527. doi: 10.1177/0962280209359860
40. Santen RJ, Yue W, Heitjan DF (2012) Modeling of the growth kinetics of occult breast tumors: role in interpretation of studies of prevention and menopausal hormone therapy. Cancer Epidemiol Biomarkers Prev 21(7):1038-1048. doi: 10.1158/1055-9965.EPI-12-0043
41. Gapstur SM, Morrow M, Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281(22):2091-2097 (Pubitemid 29264687)
42. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274(2):137-142
43. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT (2006) Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295(14):1647-1657. doi: 10.1001/jama.295.14.1647
44. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, Buist DS, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA (2003) Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. J Clin Oncol 21(23):4314-4321. doi: 10.1200/JCO.2003.05.151 (Pubitemid 46621806)
45. Reeves GK, Pirie K, Green J, Bull D, Beral V (2011) Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer. Int J Cancer. doi: 10.1002/ijc.26460
46. Burrell HC, Pinder SE, Wilson AR, Evans AJ, Yeoman LJ, Elston CW, Ellis IO (1996) The positive predictive value of mammographic signs: A review of 425 non-palpable breast lesions. Clin Radiol 51(4):277-281 (Pubitemid 26121660)
47. Cherel P, Becette V, Hagay C (2005) Stellate images: anatomic and radiologic correlations. Eur J Radiol 54(1):37-54. doi: 10.1016/j.ejrad.2004.11. 018 (Pubitemid 40424554)
48. Cui Y, Page DL, Lane DS, Rohan TE (2009) Menstrual and reproductive history, postmenopausal hormone use, and risk of benign proliferative epithelial disorders of the breast: A cohort study. Breast Cancer Res Treat 114(1):113-120. doi: 10.1007/s10549-008-9973-9
49. Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL (2008) Conjugated equine estrogen and risk of benign proliferative breast disease: A randomized controlled trial. J Natl Cancer Inst 100(8):563-571. doi: 10.1093/jnci/djn075
50. Maxwell CJ, Bancej CM, Snider J (2001) Predictors of mammography use among Canadian women aged 50-69: findings from the 1996/97 National population health survey. CMAJ 164(3):329-334 (Pubitemid 32164954)
51. Roder D, Houssami N, Farshid G, Gill G, Luke C, Downey P, Beckmann K, Iosifidis P, Grieve L, Williamson L (2008) Population screening and intensity of screening are associated with reduced breast cancer mortality: evidence of efficacy of mammography screening in Australia. Breast Cancer Res Treat 108(3):409-416. doi: 10.1007/s10549-007-9609-5 (Pubitemid 351431073)